A bivalent oral vaccine against Micropterus salmoides rhabdovirus and largemouth bass ranavirus based on yeast surface display technology
Abstract
Micropterus salmoides rhabdovirus (MSRV) and largemouth bass ranavirus (LMBV) are two major pathogens of Micropterus salmoides, for which no specific drugs or commercial vaccines are currently available. In this study, the G protein of MSRV and the MCP protein of LMBV were used as immunogens. Recombinant Saccharomyces cerevisiae strains displaying these proteins were constructed using yeast surface display technology, and the two recombinant yeasts were mixed at a 1:1 ratio to prepare a bivalent oral vaccine. Results showed that the bivalent vaccine induced G- and MCP-specific antibodies, upregulated the expression of specific immune-related genes such as IgM, IgT, and MHC II, and activated non-specific immune factors including TNFα, IL-1β, IFN1, and Mx2 in the hindgut, liver, and spleen. Challenge experiments showed that the bivalent vaccine provided a relative percent survival (RPS) of 56.7% against LMBV challenge and 80% against MSRV challenge, while also reducing tissue viral loads and alleviating the histopathological damage induced by the virus. In conclusion, this study successfully developed a safe, low-cost bivalent oral vaccine that confers immune protection against both MSRV and LMBV, showing promising application prospects.
Related
- Integrated Transcriptomics and Histological Analysis Reveals Gill Adaptation Mechanisms to Hypoxic Stress in Largemouth Bass (Micropterus salmoides)
- Ursolic acid alleviates high starch induced hepatic glucose and lipid metabolism disorders in largemouth bass (Micropterus salmoides) via the CERK/PI3K/AKT signaling pathway
- Effects of Partial Replacing Fish Meal with Dietary Degossypolled Cottonseed Protein on Growth Performance, Intestinal Barrier, Immune Function and Antioxidant Response in Largemouth Bass (Micropterus salmoides).
- Meta-analysis of gut microbiome in largemouth bass (Micropterus salmoides) under different aquaculture systems
- Epigenetic Clocks Can Predict Age in the Largemouth Bass‐Complex Despite Spatial and Sexual Variation
BibTeX
@article{gu2026bivalent,
title = {{A bivalent oral vaccine against Micropterus salmoides rhabdovirus and largemouth bass ranavirus based on yeast surface display technology}},
author = {Boge Gu and Pengzhen Yu and Hongyang Xu and Changhong Li and Jianfei Lu and Jiong Chen},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1920088},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1920088},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - A bivalent oral vaccine against Micropterus salmoides rhabdovirus and largemouth bass ranavirus based on yeast surface display technology
AU - Boge Gu
AU - Pengzhen Yu
AU - Hongyang Xu
AU - Changhong Li
AU - Jianfei Lu
AU - Jiong Chen
PY - 2026
DA - 2026/11/04
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1920088
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1920088
AB - Micropterus salmoides rhabdovirus (MSRV) and largemouth bass ranavirus (LMBV) are two major pathogens of Micropterus salmoides, for which no specific drugs or commercial vaccines are currently available. In this study, the G protein of MSRV and the MCP protein of LMBV were used as immunogens. Recombinant Saccharomyces cerevisiae strains displaying these proteins were constructed using yeast surface display technology, and the two recombinant yeasts were mixed at a 1:1 ratio to prepare a bivalent oral vaccine. Results showed that the bivalent vaccine induced G- and MCP-specific antibodies, upregulated the expression of specific immune-related genes such as IgM, IgT, and MHC II, and activated non-specific immune factors including TNFα, IL-1β, IFN1, and Mx2 in the hindgut, liver, and spleen. Challenge experiments showed that the bivalent vaccine provided a relative percent survival (RPS) of 56.7% against LMBV challenge and 80% against MSRV challenge, while also reducing tissue viral loads and alleviating the histopathological damage induced by the virus. In conclusion, this study successfully developed a safe, low-cost bivalent oral vaccine that confers immune protection against both MSRV and LMBV, showing promising application prospects.
SN - 1664-3224
ER -